Figure 2
Cumulative incidence of CMV reactivation to day +100 by prevention strategy in seropositive UCBT recipients (n = 72). Competing risk for CMV reactivation considered death or retransplantation; P value determined by the Gray test.30
Cumulative incidence of CMV reactivation to day +100 by prevention strategy in seropositive UCBT recipients (n = 72). Competing risk for CMV reactivation considered death or retransplantation; P value determined by the Gray test.30
